| Monitoring
for Adverse Reactions |
|
|
|
|
|
|
|
|
| • | Baseline
measurements |
||||||
| • | Monitor
patients at least monthly |
||||||
| • | Monitoring
for adverse reactions must be |
||||||
| individualized |
|||||||
| • | Instruct
patients to immediately report adverse |
||||||
| reactions |
|||||||